Mother-donated immune cells added to antiviral medicine for newborns with congenital CMV disease
Tests adding maternal CMV-fighting T cells to antiviral treatment in newborns with CMV disease.
Key facts
- Who runs it
- New York Medical College
- Where
- Columbus, Los Angeles, St Louis, and Vallhala, United StatesSee the 4 sites
- Trial code
- Registry title
- CMV CTLs in Neonates With CMV Infection
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 23 people, planned
- Started
- 1 Jul 2023
- Expected to end
- 31 Oct 2028
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CMV Cytotoxic T-Lymphocytes
- Anti-viral Therapy
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for newborns up to 21 days old with moderate or severe CMV infection present from birth. The mother must be able to donate immune cells that react to CMV.
- Age
- 21 days of life or younger
- Sex
- All
- Disease stage
- Moderate or severe congenital CMV disease, with at least one sign such as low platelets (≤ 50,000 mm3), enlarged liver or spleen, small head, brain changes, eye inflammation (chorioretinitis), severe hearing loss, or CMV in the brain fluid. Birth weight ≥ 2500 gms (> 1500 gms for babies small for gestational age). Gestational age ≥ 34 weeks. Blood counts and kidney and liver tests must meet set limits.
- Biomarker or test result
- CMV found by RT-PCR in urine, saliva, CSF or plasma, and/or a positive urine culture for CMV. The mother's T cells must react to CMV MACS® PepTivators, with IFN-gamma+ T cells > 0.01%.
Main reasons for not taking part
- Baby receiving steroids (> 0.5 mg/kg prednisone equivalent) on the day of the CMV CTL infusion
- Taking part in another experimental trial treating newborn CMV
- Mother with a known history of HIV infection
- Any medical condition the investigator thinks could affect taking part
- Parent or legal representative unable or unwilling to follow the protocol or give consent
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Age: ≤ 21 days of life
- Birth Weight: ≥ 2500 gms. . For babies with intrauterine growth retardation (IUGR) (small for gestational age [SGA]) > 1500 gms
- Gestational age: ≥ 34 weeks of age
- Diagnosis of CMV viremia, viruria, and/or infection:Either one or more:; Elevated CMV by RT-PCR in urine, saliva, CSF, or plasma; and/or Positive urine culture for CMV
- Moderate or Severe CMV Disease; Any one or more of the following attributable to congenital CMV infection:
- Thrombocytopenia (≤ 50,000 mm3)
- Multiple petechiae
- Hepatomegaly
- Splenomegaly
- Intrauterine growth retardation
- Increased transaminases
- Increased bilirubin
- Microcephaly
- Ventriculomegaly
- Intracerebral calcifications
- Periventricular echogenicity
- Cortical or cerebral malformation
- Chorioretinitis
- Severe neonatal hearing loss
- CMV DNA by PCR in CNS
- Increased WBC for age in CNS; Minimal Organ Criteria Hematological: ANC ≥ 750/mm3, HgB ≥ 8gm/dl, Platelets ≥ 20,000/kmm3 Renal: Serum creatinine ≤ 1.0 mg/dl Hepatic: ALT/SGOT ≤3x upper normal limits; Donor Availability: Maternal donor available with a T-cell response CMV MACS® PepTivators. the donor is considered suitable if the percentage of IFN-gamma+ T cells is > 0.01% after stimulation with PepTivators
Who cannot take part
- Patient receiving steroids (> 0.5 mg/kg prednisone equivalent) on the same day of CMV CTL infusion. Antenatal steroids for lung maturation will have been cleared prior to CMV diagnosis
- Concomitant enrollment in another experimental clinical trial investigating the treatment of neonatal CMV viremia and/or infection
- Any medical condition that could compromise participation in the study according to the investigator's assessment
- Known history of HIV infection in the mother
- Patient's legally authorized representative unwilling or unable to comply with the protocol or unable to give informed consent
Where in United States
- Nationwide Children's HosptialColumbus, United StatesContact: Masako Shimamura, MDTaking people
- Children's Hospital Los AngelesLos Angeles, United StatesContact: Ashley Gray, MDTaking people
- Washington UniversitySt Louis, United StatesContact: Carol Kao, MDTaking people
- New York Medical CollegeVallhala, United StatesContact: Mitchell Cairo, MDTaking people
About the trial
What the trial wants to find out
Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened.
Read full original descriptionShow less
All patients will receive treatment with valganciclovir or ganciclovir. There is a safety run in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2 for randomization to receive antiviral therapy with or without CMV CTLs. There is a cross-over design for patient assigned to SOC only if they have persistent disease.
Funding source: FDA OOPD
The 4 groups in the trial
- Cohort 1 Safety Run-inTreatment being tested
The first 3 patients enrolled will receive both anti-viral medication and CMV CTLs, and treatment will be staggered every 28 days from the last dose of CMV CTLs from the prior patient.
Treatment: CMV Cytotoxic T-Lymphocytes and Anti-viral Therapy
- Cohort 2 Antiviral medication + CMV CTLsTreatment being tested
Patients will receive both anti-viral medication and CMV CTLs
Treatment: CMV Cytotoxic T-Lymphocytes and Anti-viral Therapy
- Cohort 2 Antiviral medication onlyExisting treatment, for comparison
Patients will only receive anti-viral therapy
Treatment: Anti-viral Therapy
- Cross-OverTreatment being tested
Patients assigned to the SOC may be eligible to cross-over to the CVM CTL treatment if they are not responding to SOC treatment with continued elevated CMV levels.
Treatment: CMV Cytotoxic T-Lymphocytes and Anti-viral Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase II Open-Label Randomized Study of Anti-Viral Antibiotic Therapy With and Without Familial (Maternal) Cytomegalovirus (CMV) Cytotoxic T Lymphocytes (CTLs) in Neonates With Moderate/Severe Maternal Acquired CMV Infection
- Plain-language title
- Mother-donated immune cells added to antiviral medicine for newborns with congenital CMV diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 28 October 2026